Innoviva INVA
NASDAQ INVA
$21.33 -0.02 (-0.09%)
As of: Sep 4, 2026 · 3:59 PM EDT

Innoviva (INVA) Other Non Operating Income (2011 - 2026)

Innoviva's (INVA) quarterly Other Non Operating Income came in at -$366000.0 in Q1 2026, up 63.25% YoY from -$224191.9 in Q1 2025, and up 83.75% on a QoQ basis from -$2.3 million in Q3 2025.

Analysis

Innoviva (INVA) Other Non Operating Income (2011 - 2026) Analysis & Trends

Innoviva (INVA) has 16 years of Other Non Operating Income data on file, last reported at -$366000.0 in Q1 2026.

  • Quarterly Other Non Operating Income rose 63.25% year-over-year to -$366000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$4.4 million (up 30.61% YoY) and the FY2025 annual result came in at $324000.0, up 260.0% from the prior year.
  • Other Non Operating Income grew to -$366000.0 in Q1 2026, from -$2.3 million in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $266.7 million in Q3 2022 to a low of -$4.3 million in Q3 2023.
  • A 5-year average of $20.8 million and a median of -$1.1 million in 2024 frame the typical range for Other Non Operating Income.
  • Annual changes were most pronounced in 2023 — Other Non Operating Income plunged 438.4% — and 2026, when it jumped 63.25%.
  • Tracing INVA's Other Non Operating Income over 5 years: stood at $266.7 million in 2022, then slumped by 101.61% to -$4.3 million in 2023, then gained by 27.19% to -$3.1 million in 2024, then rose by 27.89% to -$2.3 million in 2025, then jumped by 83.75% to -$366000.0 in 2026.
  • The last three Other Non Operating Income figures came in at -$366000.0 (Q1 2026), -$2.3 million (Q3 2025), and -$777000.0 (Q2 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn
10 Innoviva 1.56 Bn 984.81 Mn 90.62 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -15,000.00
Mar 31, 2026 -366,000.00
Sep 30, 2025 -2.25 Mn
Jun 30, 2025 -777,000.00
Mar 31, 2025 -996,000.00
Sep 30, 2024 -3.12 Mn
Jun 30, 2024 -973,000.00
Mar 31, 2024 -1.24 Mn
Sep 30, 2023 -4.29 Mn
Jun 30, 2023 -1.90 Mn
Mar 31, 2023 -1.35 Mn
Sep 30, 2022 266.70 Mn
Jun 30, 2022 -528,000.00
Mar 31, 2022 -20.66 Mn
Sep 30, 2021 -2.04 Mn
Jun 30, 2021 -951,000.00
Mar 31, 2021 -433,000.00
Dec 31, 2020 -433,000.00
Sep 30, 2020 -13,000.00
Jun 30, 2020 30,000.00